1. South Korea Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Daihan Pharmaceutical Co., Ltd.

Daihan Pharmaceutical Co., Ltd.

KKRX:023910
25,300.00
KRW
-100.00
(-0.39%)
4,588.16EPS
6.18P/E
166.70BMarket Cap
Nov 18Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
17,824.62
18,621.1
20,712.34
23,240.41
24,074.81
26,453.29
28,124.32
27,681.89
28,574.09
30,791.79
33,315.47
34,724.94
35,476.08
35,959.13
Basic EPS, GAAP
1,297
1,737
2,296
2,943
4,139
4,753
4,694
2,897
3,778
4,171
4,834
5,741
4,701
4,588.16
Free Cash Flow per Basic Share
-1,090.39
-165.57
2,335.54
1,004.5
-98.71
-291.29
2,992.84
4,711.52
4,794.06
3,405.28
2,989.54
3,374.18
81.89
531.35
Dividend per Share
60.22
120.02
150
180.01
220.01
300.39
273.84
351.35
351.29
352.25
638.01
736.18
883.41
- -
Book Value per Share
9,276.87
10,682.87
12,806.49
15,490.58
19,313.43
23,393.61
27,795.88
30,320.57
33,801.34
38,333.01
42,172.46
46,937.72
51,056.74
51,217.58
Tangible Book Value per Share
9,205.58
10,612.49
12,736.88
15,421.71
19,245.31
23,326.23
27,729.14
30,254.32
33,735.17
38,265.49
42,104.94
46,870.2
50,989.22
51,150.06
Basic Weighted Avg Shares
6
6
6
6
6
6
6
6
6
6
6
6
6
6
Sales/Revenue/Turnover
106,803
111,709
124,276
139,437
144,439
158,720
168,762
166,080
171,463
184,268
195,911
204,195
208,614
211,440
Operating Margin (%)
11.78
12.48
15.04
15.58
22.33
22.82
19.93
18.04
16.95
17.89
18.27
18.65
14.95
14.1
Depreciation Expense
3,527
3,987
4,491
5,073
7,588
8,793
10,777
11,300
11,411
9,208
8,663
7,282
9,221
10,498
Net Income, GAAP
7,771
10,420
13,776
17,657
24,832
28,518
28,167
17,381
22,670
24,961
28,426
33,759
27,644
26,978
Effective Tax Rate (%)
19.17
20.85
21.99
17.05
22.53
23.32
24.14
22.86
25.51
25.38
22.61
20.25
16.62
16.07
Profit Margin (%)
7.28
9.33
11.09
12.66
17.19
17.97
16.69
10.47
13.22
13.55
14.51
16.53
13.25
12.76
Working Capital
14,568
19,590
30,056
25,361
40,050
49,471
68,414
82,460
101,420
113,200
118,604
94,722
114,985
121,065
LT Debt
10,059
12,000
10,000
6,800
12,400
24,000
24,800
20,817
14,000
4,000
- -
3
- -
18
Total Equity
55,661
64,097
76,839
92,943
115,881
140,362
166,775
181,923
202,808
225,398
247,974
275,994
300,214
301,159
Return on Invested Capital (%)
14.19
12.83
15.33
17.34
19.82
17.05
13.19
11.11
9.72
10.44
11.27
11.36
8.89
8.49
Return on Capital (%)
11.37
12.83
15.44
17.8
20.58
18.59
15.28
8.73
10.54
11.09
11.86
12.89
9.6
9.31
Return on Common Equity (%)
15.03
17.4
19.55
20.8
23.78
22.26
18.34
9.97
11.79
11.66
12.01
12.89
9.6
9.31

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
20
13
30
LT Borrowings
- -
- -
- -
LT Finance Leases
3
- -
18
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
6
6
6
Market Capitalization
182,280
171,990
166,698

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
154,895
158,492
167,494
Cash, Cash Equivalents & STI
86,224
89,535
98,660
Accounts Receivable, Net
31,853
31,001
30,029
Inventories
33,396
33,933
35,142
Total Current Liabilities
43,641
43,508
46,429
Payables & Accruals
- -
- -
- -
ST Debt
20
13
30
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.74%
10.54%
8.78%
Free Cash Flow
-116.77%
-25.17%
-97.57%
Net Income, GAAP
9.92%
11.01%
-18.11%
Sales/Revenue/Turnover
5.38%
4.68%
2.16%
Total Cash Common Dividend
- -
- -
20%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
49,017
48,883
54,849
51,445
204,195
2025
49,889
51,493
56,174
51,057
208,614
2026
52,715
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,406
1,364
1,443
1,528.61
5,741
2025
1,300
1,054.94
1,482.8
863.2
4,701
2026
1,187.22
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
736.18
2025
- -
- -
- -
- -
883.41
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Seung-Young Lee
Full Time Employees
737
Sector
Health technology
Industry
Medical specialties
Address
3, Seonyu-ro 45-gil Seoul SL South Korea 07209
IPO Date
Nov 23, 1994
Website
daihan.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Daihan Pharmaceutical Co., Ltd. engages in the manufacture, distribution, and sale of pharmaceutical products and related healthcare solutions, with a focus on infusion therapies and injectable medications. The company develops and supplies a broad portfolio that includes basic and specialized infusions, nutrient and electrolyte solutions, anesthetics, analgesics, anti-inflammatory and antispasmodic agents, vitamins and minerals, hepatic protectants, hypnotics and sedatives, and ophthalmic, topical, and respiratory preparations; it also provides solutions for artificial kidney dialysis, irrigation fluids, and related equipment and containers. Daihan operates across multiple stages of the value chain—from product development and clinical support to manufacturing, quality assurance, and distribution of pharmaceutical products and infusion-related components. Headquartered in Seoul, South Korea, Daihan Pharmaceutical maintains production and distribution capabilities that serve domestic and international markets. The company has a long-standing heritage dating back to its founding in 1945, and maintains an integrated platform that emphasizes safety, stability, and accessibility of infusion therapies and injectable medicines. Recent strategic activities include partnerships and alliances to expand manufacturing capacity and product reach; targeted expansions in infusion-related product lines and contract manufacturing capabilities; and ongoing investment in research and development to enhance formulation science and container technology. Daihan also leverages its regulatory and quality systems to support product launches and market expansion across its core therapeutic areas. Subsidiaries and affiliated units contribute to a broader network that supports cross-border distribution and market access in Asia and beyond.